Fig. 1 · Structure

Documents & Downloads

Sclareol

Cat. No. A10831 CAS 515-03-7
Sclareol is a fragrant chemical compound found in clary sage (Salvia sclarea), from which it derives its name. It is classified as a bicyclic diterpene alcohol. Sclareol is used as a fragrance in cosmetics and perfumes and as flavoring in food. Sclareol and other similar substances may be prepared from sclareolide.Sclareol is also able to kill human leukemic cells and colon cancer cells by apoptosis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 3.21 μM Cytotoxicity against human A549 cells after 48 hrs by MTT assay [PMID: 25825934]
HeLa IC50 3.35 μM Cytotoxicity against human HeLa cells after 48 hrs by MTT assay [PMID: 25825934]
HUVEC IC50 > 50 μg/mL Growth inhibitory activity against human umbilical vein endothelial cells (HUVEC) proliferation using MTT colorimetric method [PMID: 12781184]
PC-3 IC50 0.105 μM Cytotoxicity against human PC3 cells after 48 hrs by MTT assay [PMID: 25825934]

Sclareol Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Sclareol from 3 published references. In vitro models include MCF-7 cells; C. albicans. In vivo models include female ICR mice.

Sclareol In Vitro Studies

In MCF-7 cell viability assays, Sclareol had an IC50 of 31.11 μM after 24 h and 27.65 μM after 48 h. Treatment with Sclareol at 30 μM significantly increased early and late-stage apoptotic cells after both 24 and 48 hours. Sclareol also showed an MIC of 50 μg/mL for C. albicans, C. auris, and C. parapsilosis after 24 h. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Sclareol and cell viability in MCF-7 cells

Cell-based study · MCF-7 cells [1]

MCF-7 cells were treated with Sclareol. The cell viability IC50 was 31.11 μM after 24 h and decreased to 27.65 μM after 48 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viabilityIC50 31.11 μM; 27.65 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
10-150 µM
Exposure duration
24 and 48 h
Method
were added
Vehicle
ethanol
Methods and source locations

Compound reported in the paper: Sclareol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Experimental (S11, S13, S14, S15, S17); Results (S62)

Cell viability: Cell viability; comparator: sclareol-free ethanol — Experimental (S13); Results (S62)

Sclareol minimum inhibitory concentration against Candida species

Cell-based study · C. albicans (KCTC7965) [2]

Sclareol was tested against C. albicans in a well plate assay. The reported MIC was 50 μg/mL for C. albicans, C. auris, and C. parapsilosis after 24 h.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
minimum inhibitory concentration (MIC)MIC 50 μg/mL[2]

Literature-Reported Treatment Conditions

Treatment concentration
3.125–200 µg/mL
Exposure duration
at 30 °C for 24 h
Method
added into each well of a 96-well plate
Vehicle
dimethyl sulfoxide
Methods and source locations

Compound reported in the paper: Sclareol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.2. Anti-Fungal Susceptibility Microdilution Assay (S6, S8, S9, S11); 3. Results > 3.1. Sclareol Inhibited the Growth of Candida spp. (S62); Table 2 (T2.h1, T2.h2, T2.r1)

minimum inhibitory concentration (MIC): minimum inhibitory concentration (MIC); comparator: Growth control without sclareol treatment and sterilized medium control — 2. Materials and Methods > 2.2. Anti-Fungal Susceptibility Microdilution Assay (S9); 3. Results > 3.1. Sclareol Inhibited the Growth of Candida spp. (S62); Table 2 (T2.h1, T2.h2, T2.r1)

Sclareol and Apoptosis in MCF-7 Cells

Cell-based study · MCF-7 cells [1]

MCF-7 cells were incubated with Sclareol at 30 μM. Early and late-stage apoptotic cells increased significantly after both 24 and 48 hours.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
early and late-stage apoptotic cellsReported result a significant increase in both the early and late-stage apoptotic cells was observed after incubation with 30 μM of sclareol both for 24 and 48 hours.[1]

Literature-Reported Treatment Conditions

Treatment concentration
30 µM
Exposure duration
24 and 48 hours
Vehicle
ethanol
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Sclareol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Experimental (S11, S29, S31); Results (S72); Figure 2 legend (S115)

early and late-stage apoptotic cells: early and late-stage apoptotic cells; comparator: control cells — Results (S72)

Sclareol In Vivo Studies

Female ICR mice received Sclareol orally at 150 mg/kg before acetic acid induction. The reported writhing count over 30 min was 36.2 ± 19.8, with the compound effect isolated by comparison with the model control group. [3]

Sclareol in Acetic Acid-Induced Writhing

Animal study · female ICR mice [3]

Female ICR mice received Sclareol orally at 150 mg/kg before acetic acid induction. The reported writhing count over 30 min was 36.2 ± 19.8, with the compound effect isolated by comparison with the model control group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Writhing Times/30 minReported result Acetic Acid-Induced; Sclareol 150 mg/kg; Writhing Times/30 min: 36.2 ± 19.8 #[3]

Conditions shared by the study groups

Route
orally
Treatment course
15 min before induction
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Sclareol 150 mg/kgmodel controlAcetic Acid-Induced; Sclareol 150 mg/kg; Writhing Times/30 min: 36.2 ± 19.8 #[3]
Sclareol 150 mg/kg
Model: female ICR mice
Reported limits: Not stated in the sentences used: vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: Sclareol

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.9. Acetic Acid-Induced Writhing Test (S36, S37); 3. Results > 3.8. Effect of Sclareol on Acetic Acid-Induced Writhing Test (S88); Table 1 (T1.h1, T1.h2, T1.r5)

Writhing Times/30 min: Writhing Times/30 min; comparator: model control — 2. Materials and Methods > 2.9. Acetic Acid-Induced Writhing Test (S36); Table 1 (T1.h1, T1.h2, T1.r5)

Sclareol 150 mg/kg · 2. Materials and Methods > 2.9. Acetic Acid-Induced Writhing Test (S36); Table 1 (T1.h1, T1.h2, T1.r5)

Specifications

Manufacturer Adooq Bioscience
CAS Number 515-03-7
Formula C20H36O2
Molecular Weight 308.5
SMILES
C[C@]12CCCC([C@@H]1CC[C@@]([C@@H]2CC[C@](C)(C=C)O)(C)O)(C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 59 mg/mL (191.25 mM)
Water Insoluble
Ethanol Warmed: 23 mg/mL (74.55 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Sclareol Research References

  1. [1] Afshari H, Nourbakhsh M, Salehi N, et al. STAT3-mediated Apoptotic-enhancing Function of Sclareol Against Breast Cancer Cells and Cell Sensitization to Cyclophosphamide. Iran J Pharm Res (2020). PMID: 32922496 DOI: 10.22037/ijpr.2020.112587.13843 Source material
  2. [2] Kim C, Kim JG, Kim KY. Anti-Candida Potential of Sclareol in Inhibiting Growth, Biofilm Formation, and Yeast-Hyphal Transition. J Fungi (Basel) (2023). PMID: 36675919 DOI: 10.3390/jof9010098 Source material
  3. [3] Wong J, Chiang YF, Shih YH, et al. Salvia sclarea L. Essential Oil Extract and Its Antioxidative Phytochemical Sclareol Inhibit Oxytocin-Induced Uterine Hypercontraction Dysmenorrhea Model by Inhibiting the Ca2+-MLCK-MLC20 Signaling Cascade: An Ex Vivo and In Vivo Study. Antioxidants (Basel) (2020). PMID: 33066489 DOI: 10.3390/antiox9100991 Source material

Added to your cart

View Cart Checkout
Loading...